Literature DB >> 15897234

N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.

Jason J Christiansen1, Sigrid A Rajasekaran, Landon Inge, Lirong Cheng, Gopalakrishnapillai Anilkumar, Neil H Bander, Ayyappan K Rajasekaran.   

Abstract

Prostate-specific membrane antigen (PSMA) is an important biomarker expressed in prostate cancer cells with levels proportional to tumor grade. The membrane association and correlation with disease stage portend a promising role for PSMA as an antigenic target for antibody-based therapies. Successful application of such modalities necessitates a detailed knowledge of the subcellular localization and trafficking of target antigen. In this study, we show that PSMA is expressed predominantly in the apical plasma membrane in epithelial cells of the prostate gland and in well-differentiated Madin-Darby canine kidney cells. We show that PSMA is targeted directly to the apical surface and that sorting into appropriate post-Golgi vesicles is dependent upon N-glycosylation of the protein. Integrity of the microtubule cytoskeleton is also essential for delivery and retention of PSMA at the apical plasma membrane domain, as destabilization of microtubules with nocodazole or commonly used chemotherapeutic Vinca alkaloids resulted in the basolateral expression of PSMA and increased the uptake of anti-PSMA antibody from the basolateral domain. These results may have important relevance to PSMA-based immunotherapy and imaging strategies, as prostate cancer cells can maintain a well-differentiated morphology even after metastasis to distal sites. In contrast to antigens on the basolateral surface, apical antigens are separated from the circulation by tight junctions that restrict transport of molecules across the epithelium. Thus, antigens expressed on the apical plasma membrane are not exposed to intravenously administered agents. The ability to reverse the polarity of PSMA from apical to basolateral could have significant implications for the use of PSMA as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897234     DOI: 10.1158/1535-7163.MCT-04-0171

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  11 in total

1.  Mechanism underlying inhibition of intestinal apical Cl/OH exchange following infection with enteropathogenic E. coli.

Authors:  Ravinder K Gill; Alip Borthakur; Kim Hodges; Jerrold R Turner; Daniel R Clayburgh; Seema Saksena; Ayesha Zaheer; Krishnamurthy Ramaswamy; Gail Hecht; Pradeep K Dudeja
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

2.  Abnormal Golgi pH Homeostasis in Cancer Cells Impairs Apical Targeting of Carcinoembryonic Antigen by Inhibiting Its Glycosyl-Phosphatidylinositol Anchor-Mediated Association with Lipid Rafts.

Authors:  Nina Kokkonen; Elham Khosrowabadi; Antti Hassinen; Deborah Harrus; Tuomo Glumoff; Thomas Kietzmann; Sakari Kellokumpu
Journal:  Antioxid Redox Signal       Date:  2018-02-12       Impact factor: 8.401

Review 3.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling.

Authors:  Danni L Meany; Laszlo Hackler; Hui Zhang; Daniel W Chan
Journal:  J Proteome Res       Date:  2011-01-04       Impact factor: 4.466

Review 5.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

6.  Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.

Authors:  Mei-Hsiu Pan; Dong-Wei Gao; Jinjin Feng; Jiang He; Youngho Seo; John Tedesco; John G Wolodzko; Bruce H Hasegawa; Benjamin L Franc
Journal:  Mol Imaging Biol       Date:  2008-11-25       Impact factor: 3.488

7.  Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability.

Authors:  Sigrid A Rajasekaran; Jason J Christiansen; Ingrid Schmid; Eri Oshima; Sergey Ryazantsev; Kathleen Sakamoto; Jasminder Weinstein; Nagesh P Rao; Ayyappan K Rajasekaran
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

8.  Discriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane Antigen.

Authors:  Sonja Schmidt; Birthe Gericke; Giulio Fracasso; Dunia Ramarli; Marco Colombatti; Hassan Y Naim
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

9.  Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages.

Authors:  Olcay Boyacioglu; Christopher H Stuart; George Kulik; William H Gmeiner
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-16       Impact factor: 10.183

10.  CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers.

Authors:  L M Smith; A Nesterova; M C Ryan; S Duniho; M Jonas; M Anderson; R F Zabinski; M K Sutherland; H-P Gerber; K L Van Orden; P A Moore; S M Ruben; P J Carter
Journal:  Br J Cancer       Date:  2008-06-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.